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Erythropoietin down-regulates proximal renal tubular
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humans
Abstract
rHuEPO elevates hemoglobin concentration both by increasing red blood cell volume and by a decrease
in plasma volume. This study delineates the association of rHuEPO-induced changes in blood volumes
with changes in the renin-aldosterone system and renal function. 16 healthy males were given rHuEPO
for 28 days in doses raising the hematocrit to 48.3 (4.1) %. Renal clearance studies with urine
collections (N = 8) were done at baseline and at days 4, 11, 29, and 42. Glomerular filtration rate (GFR)
was measured by (51)Cr-EDTA. Renal clearance of lithium (C(Li)) was used as an index of proximal
tubular outflow and to assess segmental renal tubular handling of sodium and water. rHuEPO-induced
increases in hematocrit occurred from day 10 onwards and was caused by both an increase in red cell
volume and a fall in plasma volume. Well before that (from day 2 and throughout the treatment time),
rHuEPO decreased plasma levels of renin and aldosterone (N = 8) by 21 - 33 % (P < 0.05) and 15 - 36
% (P < 0.05), respectively. After cessation of rHuEPO values returned to baseline. On days 11 and 29
C(Li) increased (P < 0.02) indicating a significant 10 - 16 % decrease in absolute proximal reabsorption
of sodium and water (APR = GFR - C(Li), P < 0.05). GFR decreased slightly, albeit significantly on day
4 (P < 0.05). In conclusion, rHuEPO promptly, and before any changes in blood volumes and hematocrit
can be detected, causes a down-regulation of the renin-aldosterone system. The results are compatible
with a rHuEPO-induced reduction in proximal reabsorption rate leading to activation of the
tubuloglomerular feedback mechanism and a fall in GFR. By this, treatment with rHuEPO may result in
suppression of endogenous EPO synthesis secondary to a decrease in intrarenal oxygen consumption.
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Abstract 
rHuEPO elevates hemoglobin concentration both by increasing red blood cell volume and by a 
decrease in plasma volume. This study delineates the association of rHuEPO-induced changes in 
blood volumes with changes in the renin-aldosterone system and renal function. 16 healthy males 
were given rHuEPO for 28 days in doses raising the hematocrit to 48.3 (4.1) %. Renal clearance 
studies with urine collections (N = 8) were done at baseline and at days 4, 11, 29, and 42. 
Glomerular filtration rate (GFR) was measured by 51Cr-EDTA. Renal clearance of lithium (CLi) was 
used as an index of proximal tubular outflow and to assess segmental renal tubular handling of 
sodium and water. rHuEPO-induced increases in hematocrit occurred from day 10 onwards and was 
caused by both an increase in red cell volume and a fall in plasma volume. Well before that (from 
day 2 and throughout the treatment time), rHuEPO decreased plasma levels of renin and aldosterone 
(N = 8) by 21 – 33 % (P < 0.05) and 15 - 36 % (P < 0.05), respectively. After cessation of rHuEPO 
values returned to baseline. On days 11 and 29 CLi increased (P < 0.02) indicating a significant 10 - 
16 % decrease in absolute proximal reabsorption of sodium and water (APR = GFR - CLi, P < 0.05). 
GFR decreased slightly, albeit significantly on day 4 (P < 0.05). In conclusion, rHuEPO promptly, 
and before any changes in blood volumes and hematocrit can be detected, causes a down-regulation 
of the renin-aldosterone system. The results are compatible with a rHuEPO-induced reduction in 
proximal reabsorption rate leading to activation of the tubuloglomerular feedback mechanism and a 
fall in GFR. By this, treatment with rHuEPO may result in suppression of endogenous EPO 
synthesis secondary to a decrease in intrarenal oxygen consumption. 
 
Key Words: Aldosterone, erythropoietin, glomerular filtration rate, lithium clearance, red cell 
volume, renal tubular reabsorption, renin 
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Introduction 
Erythropoietin (EPO) is a glycoprotein produced mainly in the kidney but also in the liver and other 
tissues (1). After its release to the bloodstream EPO binds to its receptor predominantly located 
within the bone marrow where erythropoiesis is stimulated. Besides the well known actions of 
recombinant human EPO (rHuEPO) on red blood cell production, we recently demonstrated that 
rHuEPO also increases haemoglobin concentration by decreasing plasma volume (2). When 
calculating their relative contribution to the increase in haemoglobin over a 13 week period, the 
augmented red blood cell mass contributed between 46 to 62 %, and the reduction in plasma 
volume 38 – 54 % (2). Thus, their respective effects on oxygen homeostasis were surprisingly 
similar, suggesting a solid mechanism for both systems.  
 
A similar mechanism to increase arterial oxygen content is seen when humans are exposed to high 
altitude. Here haemoglobin concentration and the arterial oxygen content are increased by a fall in 
plasma volume within the first day of exposure, and after approximately 12 days an increase in red 
blood cell mass also contributes to the normalisation of haemoglobin concentration (3). It appears 
beneficial that plasma volume is decreased in the acute presence of hypoxia since such a response 
increases oxygenation rapidly as compared to a mechanism depending exclusively on augmented 
erythropoiesis. At high altitude the decrease in plasma volume is unexpectedly associated with 
decreases in renin and aldosterone (4). Although it remains at the speculative level if these changes 
are induced by endogenous EPO, our previous study using rHuEPO demonstrated that changes in 
plasma and red cell volumes were preceded by rapid decreases in these volume regulating hormones 
(2). Plasma volume is maintained within narrow limits in normal humans, and extracellular fluid 
volume is regulated through a feedback loop of afferent high and low pressure sensors located in 
cardiopulmonary, renal and hepatic tissues (5). Thus, an increase in blood pressure will lead to renal 
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sodium and water excretion. At altitude excessive sympathoexitation normally increases arterial 
blood pressure (6-7) and it is at present unknown if the changes in renin and aldosterone are related 
to this. In our previous study, however, rHuEPO-induced changes in renin and aldosterone levels 
occurred well before arterial pressure increased slightly (2). 
 
The receptor for EPO has in the last recent years been localized in noumerous non-erythroid tissues 
such the brain, retina, heart, smooth muscle cells and in the cortex, medulla, and papilla regions of 
the kidneys in humans (reviwed in (8)). In this context we have localized the receptor in human 
skeletal muscle samples and reported on induction of certain genes following EPO treatment, and 
hence suggesting a functional role of the receptor (9). Nevertheless the functionality of the EPO 
receptor has recently been questioned (10). Based on the above, we speculate that rHuEPO may 
have distinct effects on renal function besides the effect on the renin-aldosterone system. To test 
this we administered rHuEPO for four weeks in 16 healthy volunteers and examined the effects on 
blood volumes, plasma concentrations of renin and aldosterone, glomerular filtration rate and renal 
tubular reabsorbtion. 
 
 
Methods 
Subjects 
Sixteen healthy male volunteers, age 24 (3) years (mean (SD)), height 182 (6) cm, and body weight 
78 (6) kg were included. The study was approved by the Ethics Committee of Copenhagen and 
Frederiksberg, Denmark, and conformed to the Declaration of Helsinki. All subjects gave written 
informed consent to participate.  
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Protocol 
Each subject received four weeks treatment with rHuEpo (epoetin β, NeoRecormon®, Roche, 
Mannheim, Germany). RHuEpo (5,000 IU) was injected subcutaneously once every second day for 
two weeks, and thereafter once a week in experimental weeks 3 and 4, i.e. on days 0, 2, 4, 6, 8, 10, 
12, 14, 21 and 28. All injections were administered between 08:00 and 10:00 a.m. The subjects did 
not receive any iron supplementation. We have used this protocol previously to increase the 
hematocrit from around 44 % to just below 50 % (11). Venous blood samples from an antecubital 
vein were obtained prior to the first administration of rHuEPO (baseline) on two occasions 
separated by one week and on days 2, 4, 6, 10, 14, 28, 35, and 42. All blood samples were taken 
between 08:00 and 10:00 a.m. after at least 10 min of rest in the sitting position and before 
administration of rHuEPO. Blood samples were immediately centrifuged at 3000 g for 5 min and 
the plasma samples were stored at -80°C until analysis. 
 
Measurements of total haemoglobin mass and blood volumes 
Total red blood cell volume, haemoglobin mass, plasma volume and blood volume were 
determined/calculated in all subjects by a carbon monoxide (CO) re-breathing method (2) at 
baseline and on four subsequent occasions inserted between days 6-8, days 10-12, days 28-30, and 
days 42-43, respectively. At the same occasions, blood pressure (measured by sphygmomanometry) 
was recorded in the seated position after 10 min of rest. The administered volume of CO in each 
investigation was 1.3 ml kg-1 body weight. COHb, haemoglobin concentration and haematocrit 
were analysed in triplicate for each measurement by an automated system (Radiometer ABL 700, 
Radiometer, Copenhagen, Denmark). To access the variability of the method all subjects (N=16) 
were investigated twice (separated by 24 hours) at baseline before administration of rHuEPO. 
Coefficient of variation was 2.5 % for red blood cell volume.   
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Renal clearance measurements 
Renal clearance studies were performed in eight, randomly chosen subjects at baseline and on days 
4, 11, 29 and 42. The subjects refrained from smoking, alcohol and caffeine containing drinks for 
24 hours before the clearance measurements. Lithium carbonate (300 mg; 8.1 mmol) was given 
orally on the evening before each investigation. After an overnight fast, the clearance studies were 
started at 08.00 a.m. by oral intake of tab water to facilitate urine collections (250 ml every hour 
without initial load). The water intake was mantained throughout the renal clearance studies to 
produce a state of water diuresis where the urine outflow approximately equaled the water intake. 
Except for briefly standing when voiding, the subjects were confined to a resting sitting position. 
After an equilibration period of at least one hour and immediately before the investigation, the 
subjects emptied their bladder and the time was noted (T = 0 min). Thereafter, a 200 min clearance 
period was conducted. During the clearance period all urine was collected, and at the end of the 
investigation, the subjects emptied their bladder and the time was noted. Venous blood samples 
from an antecubital vein were drawn at 0, 100 and 200 min.  
 
Glomerular filtration rate (GFR) was measured by the one sample 51Cr-ethylenendiaminetetra acetic 
acid (EDTA, 3.7 MBq) clearance technique using a plasma sample drawn at 200 min after tracer 
injection (12). On two study days (at baseline and after 11 days of rHuEPO treatment), GFR was 
also calculated by a four sample 51Cr-EDTA clearance technique (13). When comparing GFR data 
obtained by the two techniques a close correlation was observed with a mean coefficient of 
variation of 3.0 %. All GFR data used in this study were generated by the one sample method. 
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Measurements of the renal clearance of lithium, used in this study as an index of proximal tubular 
fluid outflow (14), were done simultaneously with the measurements of GFR. Renal clearances of 
lithium (CLi) and sodium (CNa) were each calculated from the 200 min urinary excretion rates and 
representative values of plasma concentrations of lithium and sodium calculated as the mean from 
blood samples obtained at 0, 100 and 200 min.  
 
Analytical methods 
51Cr-EDTA activity in plasma and standards was measured in a well gamma-counter (Cobra-II, 
Pachard Instrument Company, Meriden, CT, USA). Plasma sodium was measured with a Technicon 
SMAC instrument, and urinary sodium was determined with a Technicon RA 1000 instrument 
(Tarrytown, NY, USA). Plasma and urinary lithium were measured by atomic absorption 
spectrophotometry (model 403; Perking-Elmer, Norwalk, CT, USA). Renin and aldosterone plasma 
concentrations (N = 8) were measured by ELISA kits (USCN Life Science Inc, China, and 
BioVendor Laboratory Medicine, Inc., Czech Republic, respectively). 
 
Calculations 
Reabsorption and excretion rates of sodium and water were calculated based on the assumption that 
CLi provides an accurate measurement of the rate of end-proximal delivery of fluid and sodium 
(14): Absolute proximal reabsorption rate (APR) = GFR - CLi; proximal fractional reabsorption 
(FPR) = 1 – (CLi/GFR); absolute distal reabsorption of sodium (ADRNa) = (CLi – CNa) x PNa, where 
PNa is plasma concentration of sodium; absolute distal reabsorption of water (ADRH2O) = CLi – V, 
where V is urine flow rate; fractional distal reabsorption of sodium (FDRNa) =  (CLi – CNa)/ CLi. 
Fractional excretions of sodium (FENa), lithium (FELi) and water (FEH2O) were calculated as 
CNa/GFR, CLi/GFR and V/GFR, respectively. Glomerular filtration rate of sodium and renal 
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excretion rate of sodium were determined as GFR x PNa and UNa x V, respectively, where UNa is the 
urinary concentration of sodium.  
Statistical analysis 
The effect of rHuEpo was analysed by a one-way ANOVA for repeated measures and pairwise 
comparisons versus baseline with t-tests corrected for multible comparisons (Bonferoni). Results 
are expressed as means (SD). 
 
 
Results 
Haematocrit, haemoglobin and blood volumes (Table 1 and Fig. 1). 
Haematocrit increased gradually during administration of rHuEPO. Haemoglobin concentration 
increased by 2.9 (4.4) %, 4.6 (3.8) %, and 6.6 (6.4) %, respectively, on days 6-8, 10-12, and 28-30, 
and decreased toward pre-injection values by day 42-43, still being 1.9 (6.7) % higher compared 
with baseline. These changes were the consequence of changes in plasma and red cell volumes. 
Plasma volume started to decrease by days 6-8 and was reduced by 8.0 (8.7) % on days 10-12, 
where after plasma volume gradually returned toward pre-injection levels. Red blood cell volume 
increased on days 28-30 by 7.0 (7.4) %, and remained elevated on days 42-43 by 6.2 (8.1) %. Total 
blood volume remained stable, albeit being decreased 4.4 (7.3) % on days 10-12. 
 
Arterial blood pressures and heart rate (Table 2). 
RHuEPO increased the systolic blood pressure in the post-treatment period but did not induce 
significant changes in diastolic pressure. Thus, mean arterial pressure remained unchanged 
throughout the study whereas pulse pressure increased on all study days following the initiation of 
rHuEpo injections. Heart rate decreased significantly on day 12. 
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Plasma concentrations of renin and aldosterone (Fig. 2). 
Renin and aldosterone concentrations decreased two days after the first injection of rHuEPO and 
remained reduced by 21-33 % and 15-36 %, respectively, throughout the injection period.  After 
cessation of rHuEPO treatment both renin and aldosterone returned to pre-injection values by day 
42. 
 
Glomerular filtration rate (GFR), lithium clearance and absolute proximal reabsorbtion rate (APR) 
(Figure 3). 
GFR decreased by 5.8 (1.7) % on day 4 but was unchanged compared with baseline on days 11, 29 
and 42, the percentage changes being -3.8 (2.1) %, 1.0 (2.6) %, and -1.4 (2.6) %, respectively. 
Lithium clearance increased throughout the study period, the percentage change being 13.5 (16.1) 
%, 28.0 (8.4) %, 33.1 (10.7) %, and 15.8 (17.6) % compared with baseline on days 4, 11, 29, and 
42, respectively. Fractional excretion of lithium (FELi = CLi/GFR) was 0.23  (0.06)  at baseline and 
increased to 0.26 (0.06) (day 4, NS), 0.30 (0.08) (day 11, P = 0.003), 0.30 (0.08) (day 29, P = 
0.007), and 0.25 (0.08) (day 42, NS), respectively. rHuEPO decreased APR by 8.6 (4.4) % and 12.9 
(2.6) % on days 4 and 11, whereas rHuEPO had no statistically significant effects on APR on days 
29 and 42, the percentage changes being -8.1 (2.7) % and -3.5 (6.1) %, respectively. Fractional 
proximal reabsorption (FPR = 1 – CLi/GFR) decreased significantly from 0.77 (0.06) (baseline) to 
0.74 (0.06) (day 4, NS), 0.70 (0.08) (day 11, P = 0.003), 0.70 (0.08) (day 29, P = 0.007), and 0.75 
(0.08) (day 42, NS), respectively.  
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Urine flow rate, absolute distal reabsorption of sodium (ADRNa) and water (FDRH2O), fractional 
distal reabsorption of sodium (FDRNa), fractional excretions of sodium (FENa) and water (FEH2O), 
and renal filtration and excretion rates of sodium (Table 3). 
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Urine flow rate was consistently decreased by between 26.1 (35.7) % (day 11) and 28.7 (34.4) % 
(day 4) throughout the duration of the study compared with baseline measurements. ADRNa and 
ADRH2O increased significantly on days 11 and 29. rHuEPO also significantly increased FDRNa 
from day 4 onwards. FENa remained unchanged but FEH2O decreased in all experimental conditions 
following baseline measurements. rHuEPO had no effect on overall filtration and excretion rates of 
sodium. 
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Discussion 
The haematopoietic effect of  EPO and rHuEPO has been known for five decades (15) but still the 
exact mechanisms for regulation of EPO synthesis in the kidneys remain unclear. The present study 
suggests that abundant levels of circulating EPO in normal subjects possess intrinsic effects in the 
kidneys leading to a reduction in proximal tubular reabsorption rate and a fall in GFR. These effects 
were associated with marked decreases in circulating levels of renin and aldosterone. In addition, 
we confirmed our previous observation that rHuEPO in normal subjects produces arterial 
hypertension and a reduction in plasma volume (2). Moreover, the current study delineated the time 
course of these changes: rHuEPO promptly, and before any changes in hematocrit, blood volumes 
and blood pressure can be detected, causes a down-regulation of the renin-aldosterone system, 
proximal tubular reabsorption and GFR.  
 
The effect of rHuEPO on arterial blood pressure has been demonstrated to occur independent of its 
haematopoietic effect and subsequent effect on blood viscosity (16). Recently, we reported that also 
short-time administration of very high doses of rHuEPO (30,000 IU/day for three days) increases 
arterial blood pressure and the blood pressure response to exercise to a similar extent as prolonged, 
low-dose rHuEPO for three month (17). The exact mechanisms remains unclear, but may involve 
rHuEPO-induced release of endothelin (18) and inhibition of eNOS mediated production of NO 
(19-20).  
 
The early rHuEPO induced reduction of renin and aldosterone was not caused by changes in plasma 
and blood volumes. A fall in intravascular volume normally leads to the opposite effect due to a 
decreased NaCl load to the macula densa and an increased sympathetic stimulation of the 
juxtaglomerular apparatus (23). Studies in patients with chronic kidney disease and end-stage renal 
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disease mostly revealed unchanged levels of renin and aldosterone during treatment with rHuEPO 
(reviewed by Rosario & Epstein (21)) but some studies have reported a reduction in plasma renin 
activity (21-24). The link between administration of rHuEPO and the renin-angiotensin-aldosterone 
system is interesting because the production of endogenous EPO is regulated by this system (5). 
Administration of angiotensin II in humans stimulates EPO synthesis (25-26) and, conversely, 
inhibitors of angiotensin converting enzyme and angiotensin II receptors decrease the plasma 
concentration of endogenous EPO (27-28). In patients with type-1 diabetes, an inherent high 
activity of basal renin-angiotensin system (in part governed by genetic factors) was associated with 
higher levels of EPO compared to patients with a low activity of basal renin-angiotensin system 
(29). Data from the present study confirm those obtained previously (2) suggesting that rHuEPO 
may activate an opposite pathway so as to down-regulate the activity of the renin-angiotensin-
aldosterone system independent of changes in red blood cell mass, blood volumes and blood 
pressure.     
 
The present renal clearance data indicate that the rHuEPO-induced inhibition of the renin-
angiotensin-aldosterone system is associated with a reduction of absolute proximal tubular 
reabsorption of fluid and a fall in GFR. Although a direct effect of rHuEPO on the renin producing 
cells in the juxtaglomerular apparatus cannot be excluded, it remains possible that plasma 
concentrations of renin decreased secondary to a decrease in absolute proximal reabsorption causing 
an increase in the end-proximal tubular delivery of sodium chloride and water to the macula densa. 
Changes in delivery of tubular fluid to the macula densa are well known to produce inverse changes 
in renin release (23,34,35). The decreased proximal tubular reabsorption by rHuEPO will also 
activate the tubuloglomerular feedback mechanism cauing a parallel decrease in GFR (30-31). The 
reduction in GFR is due to renal afferent arteriolar constriction mediated, in part, by increased NaCl 
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uptake and production of adenosine in the macula densa cells (34,38). The mechanisms responsible 
for direct rHuEPO effects on the proximale tubule remain unknown but may involve inhanced 
release of renal endothelin-1 (18). In low doses, endothelin-1 may suppress proximal tubular 
reabsorption of sodium (32). 
 
In a study investigating methods to detect EPO isoforms by isoelectric focusing (IEF) in human 
urine, Lasne et al (33) provided evidence indicating that prolonged treatment with rHuEPO in a 
time-dependent manner renders the IEF patterns of endogenous EPO to fade away. This strongly 
suggest a progressive inhibition of endogenous EPO synthesis following prolonged administration 
of rHuEPO. Dunn & Donelly (5) have advanced a hypothesis by which the kidney operates as a 
‘critmeter’ to sense the relative volumes of plasma and red blood cell mass and eventually regulates 
the EPO synthesis (and haematocrit) through the metabolic signal of renal tissue oxygen pressure 
(34). The hypothesis emphasizes the role of renal haemodynamics and angiotensin II in determining 
the balance between oxygen delivery and oxygen consumption in regions within the kidney 
responsible for EPO synthesis (5, 34). Thus, a decrease in filtered load by the glomeruli and a 
decrease in angiotensin II mediated reabsorption of sodium will act to decrease renal oxygen 
consumption and increase renal oxygen partial pressure, thereby decreasing the hypoxia inducible 
factor-2 dependent production of EPO by interstitial fibroblast-like cells. Based on the present data, 
we suggest that rHuEPO by inhibiting proximal tubular reabsorption, which again results in a rapid 
decline in renin and aldosterone concentrations, and in GFR, may activate a feedback system that 
serves to down-regulate the endogenous renal synthesis of EPO in the presence of high levels of 
circulating rHuEPO. Tubular reabsorption of NaCl is the major oxygen consuming process in the 
kidney, and the proximal tubule reabsorps approximately 70 % of the filtered amount of NaCl. By 
acting on the proximal tubule EPO directly reduces the major oxygen consuming process in the 
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kidney. In addition, inhibition of proximal reabsorption will, through the increased end-proximal 
delivery of NaCl to the macula densa, lead to a reduction in renin secretion and in GFR. The 
decreased renin secretion will decrease the angiotensin II and aldosterone dependent reabsorptive 
processes in the more distal neprhon segments, and the reduced GFR will lower the filtered load, 
also contributing to an overall reduction in tubular reabsorption of NaCl. It is therefore to be 
expected that the result will be an increased oxygen tension in the renal tissue. 
 
It has been suggested that the reduction in plasma volume induced by rHuEPO may be caused by 
the hyporeninemic hypoaldosteronism leading to natriuresis (2, 16). In the present study we did not 
observe such an effect. In fact, the renal excretion of sodium remained unchanged throughout the 
study period. However, in the present study we did not perform actual sodium balance studies. It is  
therefore not possible to exclude that the net effect of rHuEPO was to cause a negative sodium 
balance during the entire 28 days treatment period. The renal sodium loss necessary to account for 
the observed decrease in plasma volume is small, and may easily escape detection by the present 
clearance protocol. 
 
In summary, the present study for the first time demonstrates that prolonged treatment with 
rHuEPO in normal subjects produces a reduction of GFR and a decrease in proximal tubular 
reabsorption rate. The results suggest that rHuEPO may have a direct effect on the proximal tubule 
leading to increased end-proximal tubular flow to the macula densa, thereby reducing renin 
secretion and GFR. The resulting fall in proximal reabsorption together with a reduced filtered load 
and a decrease in angiotensin II and aldosterone dependent tubular reabsorption would increase 
oxygen tension in the environment of renal EPO producing cells and in this way initiate an 
appropriate signal for down-regulation of endogenous EPO synthesis when circulating levels are 
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high. Perhaps a similar mechanism is responsible for the rapid drop in high endogenous EPO levels 
observed after short time in high-altitude hypoxia despite sustained exposure to hypoxia (42). 
Further studies are warranted to explore intrarenal oxygen metabolism following administration of 
rHuEPO. 
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Table 1. Haematocrit, haemoglobin concentration [Hb], and blood volumes before (baseline) and 
following 4 weeks of rHuEpo treatment. N = 16. Values are means (SD). *P < 0.05 compared with 
baseline values. 
 
 
 
Time after first rHuEPO administration 
 Baseline Days 6-8 Days 10-12 Days 28-30 Days 42-43 
Haematocrit, % 
 
45.3 (2.6) 46.6 (3.1)* 47.4 (3.0)* 48.3 (4.1)* 46.1 (2.9) 
[Hb], g.dl-1 
 
14.8 (0.9) 15.2 (1.0)* 15.5 (1.1)* 15.8 (1.4)* 15.1 (1.0) 
Plasma volume 
(ml) 3558 (357) 3455 (347) 3268 (408)* 3389 (516) 3636 (381) 
Red blood cell 
volume (ml) 2949 (334) 3019 (370) 2941 (333) 3151 (373)* 3112 (351)* 
Blood volume (ml) 
 
6508 (603) 6474 (603) 6210 (649)* 6539 (726) 6748 (616) 
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Table 2. Arterial blood pressures and heart rate before (baseline) and following 4 weeks of rHuEpo 
treatment. N = 16. Values are means (SD). *P < 0.05; **P < 0.01 compared with baseline values. 
 
 
 
Time after first  rHuEpo administration 
 Baseline Day 8 Day 12 Day 29 Day 42 
Systolic blood pressure 
(mmHg) 
127 (10) 133  (8) 131 (9) 140 (12)** 140 (8) ** 
Diastolic blood pressure 
(mmHg) 
79 (7) 78 (10) 75 (7) 72 (7) 75 (5) 
Mean arterial pressure 
(mmHg) 95 (7) 97 (9) 94 (7) 94 (8) 97 (6) 
Pulse pressure (mmHg) 49 (6) 55 (6) * 56 (7) ** 68 (7) ** 66 (6) ** 
Heart rate (beats.min-1) 72 (13) 69 (14) 61 (6) * 65 (7) 65 (5) 
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Table 3. Urine flow rate, absolute distal reabsorption of  sodium (ADRNa) and water (ADRH2O), 
fractional distal reabsorption of sodium (FDRNa), fractional excretions of sodium (FENa) and water 
(FEH2O), glomerular filtration rate of sodium and renal excretion rate of sodium before (baseline) 
and following 4 weeks of rHuEpo treatment. N = 8. Values are means ± SD. *P < 0.05; **P < 0.01;  
+P < 0.005 compared with baseline values. 
 
 
 Time after first  rHuEpo administration 
 Baseline Day 4 Day 11 Day 29 Day 42 
Urine flow rate 
(ml.min-1)  
7.1 (0.8) 4.2 (0.6)** 5.3 (0.6)** 4.8 (1.5)** 4.7 (2.2)** 
ADRNa (mmol.min-1) 
 
3.60 (0.97) 3.92 (0.99) 4.39 (1.01)* 4.83 (1.38)* 3.88 (1.18) 
ADRH2O (ml.min-1) 
 
21.1 (7.8) 24.7 (7.2) 30.7 (11.2)+ 31.9 (10.6)** 25.0 (9.5) 
FDRNa  
 
0.94 (0.01) 0.95 (0.02)** 0.96 (0.02)** 0.95 (0.01)* 0.95 (0.02)* 
FENa  
 
0.014 (0.004) 0.012 (0.005) 0.012 (0.005) 0.014 (0.006) 0.012 (0.008) 
FEH2O 
 
0.057 (0.009)  
0.042 
(0.015)** 
0.043  
(0.009)* 
0.041  
(0.013)** 
0.042 
(0.018)** 
Filtration rate of Na+ 
(mmol.min-1) 
16.7 (1.2) 16.1 (1.0) 16.5 (1.0) 17.0 (1.3) 16.4 (1.2) 
Excretion rate of Na+ 
(mmol.min-1) 
0.23 (0.06) 0.19 (0.10) 0.20 (0.08) 0.25 (0.10) 0.21 (0.13) 
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Figure legends 
Figure 1. Relative changes in blood volumes. N = 16. Values are means (SD). *P < 0.05 compared 
with baseline. 
 
Figure 2. Plasma concentrations of renin and aldosterone before (0) and after 2, 4, 6, 10, 14, and 28  
days of treatment with rHuEpo and after 1 week (Day 35), 2 weeks (Day 42), and 3 weeks (Day 49)  
after the last injection. N = 8. Values are means (SD). *P < 0.05 compared with baseline.  
 
Figure 3.  Glomerular filtration rate (A), lithium clearance (B), and absolute proximal reabsorbtion 
rate (C) before injections with rHuEpo (baseline) and following 4 weeks of rHuEpo treatment (days 
11 and 29) and again after two weeks with no injections (day 42). N = 8. Values are means (SD). *P 
< 0.05 compared with baseline values. 
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Figur 2 
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Figur 3 
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